Introduction {#tca12492-sec-0006}
============

Lung cancer is a leading cause of death globally. Non‐small cell lung cancer (NSCLC) is the most frequent type, accounting for approximately 80--85%.[1](#tca12492-bib-0001){ref-type="ref"}, [2](#tca12492-bib-0002){ref-type="ref"}Squamous cell carcinoma and adenocarcinoma are the main types of NSCLC.[3](#tca12492-bib-0003){ref-type="ref"}The five‐year overall survival (OS) rate associated with NSCLC is a dismal 11%, in spite of enormous breakthroughs in treatment techniques.[4](#tca12492-bib-0004){ref-type="ref"}, [5](#tca12492-bib-0005){ref-type="ref"} Therefore, there is an urgent need to find novel targets important to the progression and development of NSCLC.[6](#tca12492-bib-0006){ref-type="ref"}

MicroRNAs (miRNAs) are a set of non‐coding RNA molecules that are small (\<22 nt) yet significant in many biological processes.[7](#tca12492-bib-0007){ref-type="ref"} MiRNA usually exerts its function by means of base pairing with the 3′‐untranslated region (3′‐UTR) of corresponding genes.[8](#tca12492-bib-0008){ref-type="ref"} Accumulated evidence has shown that the alteration or dysfunction of miRNAs might play a vital role in the cell cycle, progression, apoptosis, autophagy, and migration and invasion.[9](#tca12492-bib-0009){ref-type="ref"}, [10](#tca12492-bib-0010){ref-type="ref"}, [11](#tca12492-bib-0011){ref-type="ref"} Moreover, abnormal miRNA expression has been observed in the progression and development of certain types of cancer and tumors, including esophageal and lung cancers, lymphocytic leukemia, and neuroblastoma.[12](#tca12492-bib-0012){ref-type="ref"}, [13](#tca12492-bib-0013){ref-type="ref"}, [14](#tca12492-bib-0014){ref-type="ref"}, [15](#tca12492-bib-0015){ref-type="ref"}

The expression of the 64‐kDa protein *PDCD4* is dramatically downregulated in numerous cancers, including colorectal, lung, gastric, and breast cancers, and is therefore generally recognized as a vital tumor suppressor.[16](#tca12492-bib-0016){ref-type="ref"}, [17](#tca12492-bib-0017){ref-type="ref"}, [18](#tca12492-bib-0018){ref-type="ref"}, [19](#tca12492-bib-0019){ref-type="ref"} To date, a set of miRNAs have been confirmed to target *PDCD4*, such as miR‐96 in glioma cancer, miR‐4262 in hepatocellular carcinoma, and miR‐499 in oropharyngeal cancer.[20](#tca12492-bib-0020){ref-type="ref"}, [21](#tca12492-bib-0021){ref-type="ref"}, [22](#tca12492-bib-0022){ref-type="ref"} Although miR‐155 and *PDCD4* have been shown to play distinct roles in NSCLC, the exact mechanism of miR‐155/*PDCD4* is not yet clear.[16](#tca12492-bib-0016){ref-type="ref"}, [23](#tca12492-bib-0023){ref-type="ref"} Therefore, we assessed the effects of miR‐155and *PDCD4* on cell proliferation and invasion in NSCLC.

Methods {#tca12492-sec-0007}
=======

Cell culture {#tca12492-sec-0008}
------------

We cultured a normal human bronchial epithelial cell line (BEAS‐2B), as well as three NSCLC cell lines (SPC‐A‐1, A549, and H2170; Invitrogen, Carlsbad, CA, USA) in Dulbecco\'s modified Eagle medium containing 10% fetal bovine serum at 37°C with 5% CO~2~.

Tissue samples {#tca12492-sec-0009}
--------------

Between 2015 and 2016, we collected a total of 26 primary NSCLC and adjacent non‐cancerous tissues from the Department of Cardiothoracic Surgery, the First Affiliated Hospital of Nanjing Medical University. All patients provided informed consent before surgery. All tissue specimens were snap frozen immediately in liquid nitrogen. The patients did not undergo chemotherapy or radiotherapy before surgery. Experienced pathologists histologically determined both cancerous and adjacent non‐tumor tissues. This project passed Nanjing Medical University ethical censorship.

Extraction of RNA and quantitative reverse transcription‐PCR {#tca12492-sec-0010}
------------------------------------------------------------

We isolated total RNA from human tissues and cell lines using Trizol (Invitrogen). We performed quantitative real‐time PCR (qRT‐PCR) experiments on an ABI 7500 version of a fast real‐time PCR system (Stratagene, La Jolla, CA, USA) with a high‐specificity miR‐155 qRT‐PCR detection kit (Stratagene), in accordance with the manufacturer\'s protocol. U6 small nuclear RNA was chosen as a built‐in control. A 2△CT method was applied to calculate the relative gene expression level.

Plasmid construction {#tca12492-sec-0011}
--------------------

We obtained miR‐155 mimics, anti‐miR‐155 mimics, and their negative control oligonucleotides (miR‐155 NC and anti‐miR‐155 NC) from RiboBio (Guangzhou, China). We then amplified 3′‐UTR of PDCD4 messenger RNA utilizing the follow primers: forward 5′‐GAATCTAGAATATAAGAACTCTTGCAGTC‐3′ and reverse 5′‐CTTCTAGAACCAGGTTCATTTTCC‐3′. The PCR products obtained after amplification were implanted into the pGL3 control vector (Promega, Madison, WI, USA). A fast mutation kit (NEB, Ipswich, Canada) was then used for mutation experiments. Finally, we inserted *PDCD4* into the specific region of pcDNA 3.1and pcDNA3.1‐*PDCD4* was ultimately constructed.

Cell transfection {#tca12492-sec-0012}
-----------------

We divided the transfected cells into seven groups in accordance with the treatment applied: (i) miR‐155, (ii) miR‐155 NC, (iii) anti‐miR‐155, (iv) anti‐miR‐155 NC, (v) *PDCD4* 3′‐UTR‐wild, (vi) *PDCD4* 3′‐UTR‐mut, and (vii) pcDNA3.1‐*PDCD4*. We performed all transfection experiments using Lipofectamin 2000 (Invitrogen). The selection of cells transfected with miR‐155 or PDCD4 was carried out using G418 and finally, we obtained the stable transfected cells.

Western blot {#tca12492-sec-0013}
------------

Total proteins were extracted from cultured cells using a RIPA Lysis Buffer (Beyotime, Shanghai, China). A dismembrator was used to homogenize 50--100 mg of tissues to extract proteins. Protein concentration was detected using a BCA Protein Assay Kit (BioRad, Hercules, CA, USA). Equal doses of protein were obtained from samples and were transfected onto polyvinylidene fluoride membrane after sodium dodecyl sulfate‐polyacrylamide gel electrophoresis integration. The membranes were immersed in tris‐buffered saline plus tween 20 with 5% non‐fat milk for two hours. The membranes were then incubated with diluted primary antibody against *PDCD4* (Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA) at 1:400 overnight at 4°C and then with the secondary antibody for 1 hour at room temperature. The signals were visualized using ECL reagents (Pierce Biotechnology, Rockford, IL, USA).

Cell counting kit‐8 and tumor formation test {#tca12492-sec-0014}
--------------------------------------------

Cell proliferation was evaluated using cell counting kit‐8 assay (CCK‐8, Dojindo Molecular Technologies, Kumamoto, Japan). We seeded the cells into 96‐well plates at 2 × 10^3^ cells per well. The proliferation rate was measured at zero, 24, 48, and 72 hours after cell transfection. A microplate reader (BioRad) was used to determine the absorbance at 450 nm. BALB/C nude mice aged five weeks were purchased from the Experiment Animal Center of Nanjing Medical University. The Institutional Animal Care and Treatment Committee of Nanjing Medical University approved all animal protocols. We gathered the A549 cells during the logarithmic phase. Cells were washed twice using phosphate buffered saline and resuspended at a concentration of 2 × 10^7^ cells/mL. The female nude mice were then subcutaneously injected with 0.1 mL of the suspended cells at either side of their flank. The size of the tumor was measured twice a week.

Luciferase test {#tca12492-sec-0015}
---------------

We seeded the cells into 24‐well plates with 2 × 10^5^ cells per well. Cells were co‐transfected 24 hours later with *PDCD4* 3′‐UTR wild or *PDCD4* 3′‐UTR mut and anti‐miR‐155 or anti‐miR‐155 NC. We harvested the cells 48 hours after transfection and treated them using a Dual‐Luciferase Reporter Assay Kit (Promega) following the manufacturer\'s instructions.

Transwell invasion assay {#tca12492-sec-0016}
------------------------

Cell transfection was conducted with miR‐155, miR‐155 NC, and pcDNA3.1‐*PDCD4*, respectively. The transfected cells (2 × 10^5^) were placed in transwell chambers precoated with 20 μg Matrigel. The medium containing 10% fetal bovine serum located in the lower chamber was treated as chemoattractant. Non‐invading cells above the membrane were scraped off after 24 hours of incubation. The invasive cells that were attached to the bottom were tinted with 0.05% crystal violet. We then counted the number of invaded cells under an inverted microscope at ×200 magnification. Each assay was carried out in triplicate.

Statistical analysis {#tca12492-sec-0017}
--------------------

All statistical analyses were performed using SPSS version 21.0 (IBM Corp., Armonk, NY, USA). Mean values ± standard deviations were presented in all data. A student\'s *t‐*test was applied to assess differences. A *P* value of *\<* 0.05 was considered statistically significant.

Results {#tca12492-sec-0018}
=======

MiR‐155 was upregulated in non‐small cell lung cancer (NSCLC) cell lines, while PDCD *4* messenger RNA and protein levels were downregulated {#tca12492-sec-0019}
--------------------------------------------------------------------------------------------------------------------------------------------

We tested messenger RNA (mRNA) and protein in *PDCD4* and miR‐155 expression in four cell lines: a normal human bronchial epithelial cell line (BEAS‐2B) and three NSCLC cell lines (A549, H2170, and SPC‐A‐1). The level of miR‐155 expression in normal cells was lower than in NSCLC cell lines (Fig [1](#tca12492-fig-0001){ref-type="fig"}a). Inversely, the *PDCD4* mRNA level was higher (Fig [1](#tca12492-fig-0001){ref-type="fig"}b). Western blot results demonstrated a higher level of *PDCD4* protein in normal cells than in cancer cell lines (Fig [1](#tca12492-fig-0001){ref-type="fig"}c,d). These results indicated notable upregulation of miR‐155 expression in NSCLC cell lines and downregulation of *PDCD4* mRNA and protein levels.

![Relative (**a**) miR‐155 expression, (**b**) PDCD *4* messenger RNA (mRNA) and (**c**) PDCD *4* protein levels in three non‐small cell lung cancer cell lines (A549, H2170, and SPC‐A‐1) and a normal human bronchial epithelial cell line (BEAS‐2B). U6 small nuclear RNA, glyceraldehyde 3‐phosphate dehydrogenase, and β‐actin were used as internal controls, respectively. (**d**) Relative grayscale values of Western blotting were calculated to analyze the PDCD *4* protein levels in the four cell lines (\**P* \< 0.05).](TCA-8-613-g002){#tca12492-fig-0001}

Downregulation of PDCD *4* and negative correlation with miR‐155 expression in NSCLC tissues {#tca12492-sec-0020}
--------------------------------------------------------------------------------------------

To further prove that miR‐155 negatively regulates *PDCD4* not only at a transcriptional level but also at a post‐transcriptional level, we performed qRT‐PCR and Western blotting to analyze *PDCD4* mRNA, *PDCD4* protein, and miR‐155 expression in resected tumors and adjacent normal tissues in 26 NSCLC patients. The level of *PDCD4* protein was notably lower in the tumor tissues than in the corresponding normal tissues (Fig [2](#tca12492-fig-0002){ref-type="fig"}a,b). Analogously, low levels of *PDCD4* mRNA were observed in the tumor tissues compared to the adjacent normal tissues (Fig [2](#tca12492-fig-0002){ref-type="fig"}d). In contrast, we detected that miR‐155 was upregulated in NSCLC tissues compared to normal tissues (Fig [2](#tca12492-fig-0002){ref-type="fig"}c). This in vivo data further indicated that miR‐155 negatively regulates *PDCD4* at both transcriptional and post‐transcriptional levels.

![*PDCD4* protein levels in representative examples of eight out of 26 matched tumor tissues/normal (T/N) were analyzed via (**a**) Western blotting and (**b**) by calculating the grayscale Western blot values; β‐actin was used as an internal control. (**c**) Relative miR‐155 expression and (**d**) average level of PDCD *4* messenger RNA (mRNA) in non‐small cell lung cancer (NSCLC) (*n* = 26) and adjacent non‐tumor tissues (*n* = 26) assessed by quantitative reverse transcription (qRT)‐PCR. U6 small nuclear RNA and glyceraldehyde 3‐phosphate dehydrogenase were used as endogenous controls, respectively (\**P* \< 0.05).](TCA-8-613-g001){#tca12492-fig-0002}

PDCD *4* is a direct target of miR‐155 {#tca12492-sec-0021}
--------------------------------------

We presented the 3′‐UTR of *PDCD4* and its possible binding site with miR‐155 based on the bioinformatics yielded by TargetScan and miRanda (Fig [3](#tca12492-fig-0003){ref-type="fig"}a). We then conducted Western blotting and a luciferase test. Western blotting demonstrated that *PDCD4* was distinctly upregulated in H2170 and A549 cells after transfection with anti‐miR‐155 mimic (Fig [3](#tca12492-fig-0003){ref-type="fig"}b). Moreover, we further conducted a luciferase reporter test to verify whether the 3′‐UTR of *PDCD4* was a functional target of miR‐155 in NSCLC. pGL3‐*PDCD4* 3′‐UTR wild and pGL3‐*PDCD4* 3′‐UTR mut were established (Fig [3](#tca12492-fig-0003){ref-type="fig"}a). When co‐transfected with anti‐miR‐155, significantly increased luciferase activity containing *PDCD4* 3′‐UTR was observed in H2170 and A549 cells (Fig [3](#tca12492-fig-0003){ref-type="fig"}c,d). Thus, we concluded that miR‐155 combined with site of the 3′‐UTR sequence of *PDCD4* regulates the *PDCD4* level and *PDCD4* serves as a direct target of miR‐155.

![PDCD *4* was identified as a direct target of miR‐155 in non‐small cell lung cancer cell lines. (**a**) The predicted PDCD *4* 3′‐untranslated region (UTR)‐wild and PDCD4 3′‐UTR‐mut binding sequences in miR‐155. (**b**) PDCD *4* protein levels were analyzed by Western blot. β‐actin was used as an internal control. After co‐transfection with miR‐155 NC or miR‐155 and PDCD *4* 3′‐UTR‐wild or PDCD *4* 3′‐UTR‐mut (reporter vectors), the luciferase activity in (**c**) A549 and (**d**) H2170 cells was analyzed. The measured luciferase activity was normalized to renilla luciferase activity (\**P* \< 0.05).](TCA-8-613-g003){#tca12492-fig-0003}

Upregulated expression of PDCD *4* could restrain the tumor promoting effect of miR‐155 in NSCLC {#tca12492-sec-0022}
------------------------------------------------------------------------------------------------

Western blotting, CCK‐8 testing, tumor formation in nude mouse models, and transwell invasion assay were performed in order to further explore the correlation between *PDCD4* and miR‐155. After miR‐155 NC or miR‐155 were co‐transfected with pcDNA3.1‐*PDCD4*, the H2170 and A549 cells all displayed high *PDCD4* protein levels (Fig [4](#tca12492-fig-0004){ref-type="fig"}a,b). After CCK‐8 testing and transfection with pcDNA3.1‐PDCD4, the absorbance value in H2170 and A549 cells was reduced, but after co‐transfection with miR‐155 we did not observe any growth (Fig [4](#tca12492-fig-0004){ref-type="fig"}c,d). Furthermore, we set up four types of nude mouse models by injecting A549 cells into either side of the flank of female nude mice. Our results demonstrated that the tumor was reduced after transfection with pcDNA3.1‐*PDCD4*, but co‐transfection with miR‐155 did not reverse this phenomenon (Fig [4](#tca12492-fig-0004){ref-type="fig"}e). Regarding transwell invasion assay, after transfection with miR‐155, the average number of H2170 or A549 cells penetrating the transwell membrane increased. However, the average number of transwell cells after co‐transfection with pcDNA3.1‐*PDCD4* and miR‐155 reduced, which meant that the invasion effect of miR‐155 in NSCLC was abrogated (Fig [4](#tca12492-fig-0004){ref-type="fig"}f,g). Overall, these results imply that overexpression of *PDCD4* restrained the tumor‐promoting effect of miR‐155 in NSCLC.

![PDCD *4* overexpression restrains proliferation and invasion induced by miR‐155. After co‐transfection with miR‐155 NC or miR‐155 and pcDNA3.1‐PDCD *4*, the PDCD *4* protein level was analyzed by Western blot in (**a**) A549 and (**b**) H2170 cells. β‐actin was used as an internal control. Cell growth activity after co‐transfection with miR‐155 NC or miR‐155 and pcDNA3.1‐PDCD *4* was assessed using CCK‐8 assays in (**c**) A549 and (**d**) H2170 cells (\**P* \< 0.05). (**e**) Six weeks after injecting the mice with miR‐155 NC, miR‐155 NC + pcDNA3.1‐PDCD *4*, miR‐155, or miR‐155 + pcDNA3.1‐PDCD *4* group cells (2 × 106 A549 or H2170 cells), the nude mice were all sacrificed to compare the tumor volume in the four different groups (\**P* \< 0.05). The average numbers of (**f**) A549 and (**g**) H2170 cells penetrating the transwell membrane were analyzed using transwell invasion assay (\**P* \< 0.05).](TCA-8-613-g004){#tca12492-fig-0004}

Discussion {#tca12492-sec-0023}
==========

Accumulating evidence suggests that miRNAs function as either tumor suppressors or oncogenes by regulating various biological processes of cancer cells, such as cell proliferation, apoptosis, migration, and invasion.[24](#tca12492-bib-0024){ref-type="ref"}, [25](#tca12492-bib-0025){ref-type="ref"} Numerous studies have described the effect of miR‐155 in regulating the progression of varied tumors.[26](#tca12492-bib-0026){ref-type="ref"}, [27](#tca12492-bib-0027){ref-type="ref"}There has been a trend to define miR‐155 as a marker of solid and hematological malignancies for diagnosis and prognosis;[28](#tca12492-bib-0028){ref-type="ref"}however, the exact role miR‐155 plays in the occurrence and progression of NSCLC remains unknown. Therefore, illuminating the molecular mechanism in the occurrence and prognosis of NSCLC is of great importance.

We demonstrated that miR‐155 is upregulated in NSCLC cell lines, while *PDCD4* mRNA and protein levels are downregulated. Furthermore, our results showed that *PDCD4* was downregulated in NSCLC tumor tissues and was negatively correlated with miR‐155 expression. Luciferase reporter testing revealed that miR‐155 exerts its tumor‐promoting effect by directly targeting *PDCD4*. *PDCD4* overexpression reversed the malignant phenotypes of NSCLC, thus it may be a potential target for NSCLC treatment. In accordance with the results of previous studies, we confirmed that *PDCD4* is a tumor suppressor.[29](#tca12492-bib-0029){ref-type="ref"}, [30](#tca12492-bib-0030){ref-type="ref"} *PDCD4* suppresses cell invasion in colon cancer by inhibiting the expression of mitogen‐activated protein kinase. It has also been reported that *PDCD4* could inhibit cell invasion in breast cancer by suppressing metalloproteinase 2.[31](#tca12492-bib-0031){ref-type="ref"}, [32](#tca12492-bib-0032){ref-type="ref"} These results indicate that emphasis should be placed on an exploration of the relationship between *PDCD4* and miR‐155, which may cast light on the pathogenesis of NSCLC.

In conclusion, our results demonstrate the effects of miR‐155 on multiplication and invasion by targeting *PDCD4* in NSCLC. miR‐155 plays a crucial role in NSCLC tumorigenesis and could represent a potential NSCLC treatment strategy. miR‐155 and *PDCD4* (protein and mRNA) have contrasting expression levels in NSCLC tissues and cell lines. *PDCD4* is a functional target for miR‐155 and regulates proliferation or invasion by targeting *PDCD4* in NSCLC. Therefore, our data indicate that downregulating miR‐155 or upregulating *PDCD4* could be potential treatments strategies for NSCLC.
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